SHIFTING PARADIGMS IN CELL & GENE THERAPY

MAKING CHALLENGING DISEASES CURABLE - FOR EVERYONE

ABOUT US

The TQx platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the patient's side. This method uses extra-corporeal gene therapy but keeps the benefits of autologous cell therapy, where patients receive treatments made from their own cells.

Our TQx method makes it easier to create genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production.

As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were previously difficult to address, including rare autoimmune diseases and cancers.

      

OUR SCIENCE

TQx is developing a modular target cell-specific modification platform including relevant technology components for the generation of gene modified cell therapy products.

Current Challenges

- Limited availability for patients
- High burden on patient
- Exhausted cells
- Laborious manufacturing & logistics
- Expensive therapies
- Limited in indications

TQx Solution

- Accessibility for all patients
- Superior treatment experience for patients
- Better cell products
- Fast manufacturing and no logistics
- Economic therapies
- Expansion to broader indications

A major problem with current autologous cell therapeutics is their complex production.
Each therapeutic product is manufactured individually for individual patients in special GMP cleanroom facilities - which takes several weeks. On the other hand, generalized in vivo gene therapy is lacking the required high degree of target cell specificity as a prerequisite for the generation of highly effective and safe cellular medicines.

Patients are suffering from an extremely high emotional and physical toll.

TQx is shifting the less scalable, lengthy and cost-intensive "classical" pharmaceutical production of cell therapeutics to a highly automated and ultra-fast gene therapy approach, without abandoning the advantages of autologous cell therapy.
Our ultra-fast process brings the cell therapy directly to the patient instead of producing it under conventional conditions in centralized facilities with the aim of significantly simpler logistics and cost reductions. As a result, the TQx process opens opportunities for the treatment of previously unaddressed indications such as (rare) autoimmune diseases and cancer.

TQx is making cell and gene therapy broadly accessible in order to address the medical needs of many patients.

Ultra-short TQx-bed-side approach for "producing" genetically modified immune cells.

TQx

OUR TEAM

Immunologists, engineers, scientists and business developers with deep expertise in CMC, product/process development, clinical development and clinical operations for cell and gene therapies - From Biotech to Big Pharma - From Concept to Clinic

Dr. Christian Eckert

Dr. Christian Eckert

CEO & Co-Founder 

  • Christian has more than 16 years of experience in biotechnology and cell therapy with additional in-depth knowledge in the field of antibodies, small molecules, and exosomes. In addition, he has over 10 years of experience in clinical operations and clinical development. Both, his scientific expertise, and his previous position as Managing Director make him ideally suited to lead TQx as CEO.
Dr. Christian Stemberger

Dr. Christian Stemberger

CSO & Co-Founder

  • Christian has a background in Immunology with over 15 years of experience in cell therapy product and process development within Biotech and Pharma. During his past positions he gained strong experience in various aspects of technology and cell product development to bridge the gap between concept, clinical implementation and commercialization. Christian is the inventor of several field-relevant patents related to cell manufacturing and engineering.
Sabine Radisch

Sabine Radisch

CTO & Co-Founder

  • Sabine´s expertise is to build bridges between biological/medical and engineering topics. She has 13 years of experience in the field of biotechnology and cell therapy with deep expertise in technical device/product development as well as process development for cell & gene therapy generation. Sabine knowledge is also around medical device and consumables development and manufacturing management.
Dr. Stefan Dreher

Dr. Stefan Dreher

COO & Co-Founder

  • Stefan has over 14 years of experience in the field of biotechnology and cell therapy. His past position as manufacturing & supply chain lead in GMP environment qualifies him as an expert in supply chain for topics such as ancillary materials/raw materials/components in cell & gene therapy. As CMO manager, Stefan works closely with external manufacturing partners for producing components needed during a cell & gene therapy generation process.
Christin Zündorf

Christin Zündorf

Chief Business Officer

  • Christin´s expertise lies in the field of commercial strategy and organization design with over 8 years of experience in strategy consulting for the pharmaceutical & life science industry, as well as in the field of venture building. Her deep knowledge and experience working with prestigous clients in the industry contributes to shaping the future of TQ's biotech endeavors, ultimately benefiting patients, and advancing healthcare.
Theresa Kagerbauer

Theresa Kagerbauer

Associate Scientist

  • Theresa´s practical experience with more than 3 years in molecular biology & immunology is essential for contributing to TQx vision in promoting a paradigm shift in cell & gene therapy. She has built a solid knowledge foundation in Good Clinical Practice and clinical trials which helps her to connect practical experience and clinical practice. Furthermore, Theresa is an expert in lab management.

BOARD

TQ
Dr. Andreas Jenne

Andreas has launched several biotech companies, which he managed in leading positions. Among others, he was CEO of Kinaxo, a proteomics service provider that was acquired by Evotec, and NEO New Oncology, a cancer diagnostics company that was acquired by Siemens Healthcare.

TQ
Nils Sharman

Niels Sharman has been supporting the life science investment team since November 2020. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and worked for two biotech start-ups. 

TQ
Dr. Herbert Stadler

Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co founded several (biotech) companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH, Stage Cell Therapeutics GmbH and DeveloGen AG. 

SCIENTIFIC ADVISORS

TQ
Dr. Andrea Schmidts

Emmy Noether group leader & MD. CAR-T cells, cell therapy, immunotherapy, cancer research.

INVESTORS

HTGF
VENTURA

NEWS

Pantherna Therapeutics and TQ Therapeutics announce research collaboration to advance ultra-short Cell and Gene Therapy (CGT) process leveraging LNP technology (Open)

     

CONTACT

Address

Fraunhoferstr. 1
82152 Planegg

Contact

info@tqtherapeutics.com
+49.89.2488704-50

© Copyright 2024 TQ Therapeutics GmbH - All Rights Reserved
Imprint - Privacy